Matthias Guckenberger
2,337 posts
Matthias Guckenberger
@Mat_Guc
Radiation Oncologist at University Hospital Zurich @Unispital_USZ | Professor at University of Zurich @UZH_ch | @ESTRO_RT President
- SBRT for long bone mets - 111 pts 114 mets - 84 femur, 26 humerus, 4 tibia - most common doses 30-50 Gy in 5Fx 👉 2a fracture: 6.1% 👉 2a local failure: 7.2% 👉 extraosseous disease sig. associated with fracture & local failure 👍THX to all collaborators! sciencedirect.com/science/articl…
- TACE vs. SBRT for HCC: randomized phase II TRENDY trial - stoped early due to poor a accrual - all endpoints significantly or numerically better after SBRT 👉 time to progression 19 vs 12 mo 👉 median OS 44 vs 37 mo 👉2a local control 100% vs 44% CONGRATS
- ESTRO clinical practice guideline: SBRT for Spine mets 👉 Conditional rec for painful spine mets 👉 Strong rec for oligometastatic spine mets Many more details 🙏 @alongi_filippo @SahgalArjun @gminniti2012 @MaxNiyazi @umbertoricardi & all contributors ! doi.org/10.1016/j.rado…
- Will all radiotherapy be delivered in max 5 fractions only? Safe the date for virtual symposium (5 sessions of 50 min over 5 weeks): breast, prostate, lung, rectal and pancreatic cancer Faculty: C Rödel, M Brunt, N van As, M Hawkins, S Senan Registration open soon #radonc
- What is the "true" prevalence of oligometastatic disease? ▶️ Unbiased screening n=7000 PET scans acquired @Unispital_USZ ▶️ 55% (!) of all M+ PET scans are OMD ▶️ 50% with only n=1 met ▶️ c-MRI important for staging 👉 High clinical & scientific relevance redjournal.org/article/S0360-…
- Fresh from ASCO GU: PACE-A trial reporting for the first time a randomized comparison of SBRT vs prostatectomy for localised prostate cancer - improved urinary and sexual function after SBRT - increased bowel symptoms after SBRT CONGRATS to @nickva1 and study team !
- Consequence to me: 👉 WE need to initiate and tell the stories about the benefits of modern Radiation Oncology as an important pillar of interdisciplinary cancer care 👉 we CANNOT expect others doing so 👉 we = all #radonc @ESTRO_RT @ASTRO_org @ISRSy @the_RSS …Radiotherapy sentiment in @nytimes is eye-opening. Since 2009, over half of articles show negative bias towards RT, while only 1/4 are positive. Despite major advancements in tech like MR-Linac, adaptive RT, & heavy ions, media celebration is scarce. thegreenjournal.com/article/S0167-… 1/7
- COAST: Durvalumab alone or in combination with Oleclumab or Monalizumab in unresectable stage III NSCLC after RCT ORR: 17.9 % vs 30.0% 35.5% 12 mo PFS: 34% vs 63% vs 73% 👉 promising data to go beyond PACIFIC #radonc ascopubs.org/doi/pdf/10.120…
- Full publication of randomised Scandinavian dose escalation trial for LS SCLC 45Gy / 30 Fx / 3 weeks vs 60Gy / 40 Fx / 4 weeks ⬆️ 2a OS 74.2% vs 48.1% ⬆️ Med OS 37.2 mo vs 22.6 mo ↗️ Med PFS 18.6 mo vs 10.9 mo (p=0.13) ➡️ Grade 3+ toxicity and SAEs #radonc tinyurl.com/ryrfztj2
- Special issue about oligometastatic disease published by the @IJROBP 👉 THX to @sueyom and @SalmaJabbour1 for this huge effort !
- Safety of SBRT for max 5 oligometastases: SABR-5 study - n=281 pts, in 31% with > 1 oligometastasis - grade 3+ SBRT toxicity <5% - grade 2+ SBRT toxicity 18.6% 👉 I do not know any (local) treatment in metastatic pts with such a favorable safety profile ! ja.ma/3rgIV8b
- Single fraction 8Gy vs SBRT 20Gy for painful bone mets, n=126, mostly non-spine #ESTRO23 Complete pain response at 1 mo primary endpoint 👉 no difference at 1 mo 👉 improved in per protocol analysis after 3mo 👉 no increased toxicity PATIENT SELECTION IS KEY
